Author details

Full Name

Roy M Gulick

Affiliation

ORCID

Career Start Year

1989

Papers

193

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37352285	Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305.		2023
37435958	Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.	Clin Infect Dis	2023
36540980	Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain.	Pac Symp Biocomput	2023
34791296	Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.	J Antimicrob Chemother	2022
35687192	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).	AIDS Behav	2022
36410385	Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries.	Clinical Infectious Diseases	2022
34698505	Managing HIV Treatment Failure: Time to REVAMP?	Annals of Internal Medicine	2021
34127579	Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.	AIDS	2021
33901188	Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults.	PLoS Genet	2021
34224260	HIV: Closing the Mortality Gap.	Annals of Internal Medicine	2021
33831911	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.	AIDS	2021
33875975	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.	Rheumatology Advances in Practice	2021
33306564	Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.	Journal of acquired immune deficiency syndromes (1999)	2021
32744591	The Uncertain Role of Corticosteroids in the Treatment of COVID-19.	JAMA Internal Medicine	2021
33215718	Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve.	Transfusion	2021
32829410	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.	Clin Infect Dis	2021
34399058	Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence.	Annals of Internal Medicine	2021
34379922	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.	N Engl J Med	2021
30887031	Drug Costs: What Can Infectious Diseases Physicians Do?	Journal of Infectious Diseases	2020
31914799	Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.	AIDS Research and Human Retroviruses	2020
32412710	Severe Covid-19.	New England Journal of Medicine	2020
32302078	Clinical Characteristics of Covid-19 in New York City.	N Engl J Med	2020
31658110	HIV treatment and prevention 2019: current standards of care.		2020
32701969	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.	PLoS One	2020
32692726	Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City.	Journal of Clinical Investigation	2020
32864388	COVID-19 in Hospitalized Adults With HIV.	Open Forum Infectious Diseases	2020
32628537	Obesity and COVID-19 in New York City: A Retrospective Cohort Study.	Ann Intern Med	2020
31241541	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.	J Acquir Immune Defic Syndr	2019
30557160	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.	AIDS	2019
30355266	Long-Acting HIV Drugs for Treatment and Prevention.	Annual Review of Medicine	2019
31039247	Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.	Journal of Antimicrobial Chemotherapy	2019
30869200	Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions.	J Int AIDS Soc	2019
30793009	Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy.	Open Forum Infect Dis	2019
29847509	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.	Pharmacogenet Genomics	2018
30072495	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.	J Exp Med	2018
30258217	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.	Nat Med	2018
30258136	Combination therapy with anti-HIV-1 antibodies maintains viral suppression.	Nature	2018
30586364	No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305.	PLoS One	2018
30085241	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.	J Infect Dis	2018
29702493	New HIV drugs: 2018 and beyond.		2018
29253097	ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.	Clin Infect Dis	2018
29689540	Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.	Topics in antiviral medicine	2018
29455571	Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.	AIDS Res Hum Retroviruses	2018
28208122	A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.	Top Antivir Med	2017
28931220	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.	J Infect Dis	2017
28828489	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.	Ann Intern Med	2017
27811319	Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).	J Infect Dis	2017
28092665	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.	Nat Med	2017
27800523	Invasive Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature.	Open Forum Infectious Diseases	2016
27338952	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.	Nature	2016